


Targeting of tracked tumor foci ups gleason score upgrading

23 February 2017



fusion biopsy allows for heightened detection of Gleason score 4 + 3 or greater cancers," the authors write.

More information: Abstract

Full Text

Copyright © 2017 HealthDay. All rights reserved.

(HealthDay)—Targeting of tracked tumor foci allows for improved detection of Gleason score 4 + 3 or greater cancers among men under active surveillance for prostate cancer, according to a study published in the March issue of *The Journal of Urology*.

Nima Nassiri, M.D., from the University of California in Los Angeles, and colleagues examined the rate of upgrading to Gleason score 4 + 3 or greater in 259 prostate cancer patients who were diagnosed via magnetic resonance imaging (MRI)/ultrasound fusion guided biopsy from 2009 to 2015 and underwent fusion biopsy during active surveillance.

The researchers found that men with Gleason score 3+4 were 4.65 times more likely to have upgrading at three years than men with Gleason score of 3+3 (P

"During <u>active surveillance</u> of prostate cancer, targeting of tracked tumor foci by MRI/ultrasound



APA citation: Targeting of tracked tumor foci ups gleason score upgrading (2017, February 23) retrieved 27 April 2021 from https://medicalxpress.com/news/2017-02-tracked-tumor-foci-ups-gleason.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.